Prostate cancer disparities have deepened since USPSTF negative screening recommendation

Video

“Patients who really need to be screened are not getting screened,” says Ram Pathak, MD.

In this video, Ram Pathak, MD, an assistant professor at Mayo Clinic, discusses how the United States Preventative Services Task Force (USPSTF) grade D recommendation against PSA screening has resulted in a disproportionate increase in the incidence of metastatic prostate cancer among minority populations at screening.

At the 2022 AUA Annual Meeting, Pathak shared the abstract, “Racial and ethnic disparities magnified after USPSTF category D recommendation for PSA screening.”

Related Videos
Doctor consulting with patient | Image Credit: © Khunatorn - stock.adobe.com
Scott Morgan, MD, MSc, FRCPC, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Todd M. Morgan, MD, answers a question during a Zoom video interview
3D illustration of prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Matthew Loria answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Man talking with doctor | Image Credit: © DragonImages - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.